Jasper Therapeutics (JSPR) Receivables - Other (2020 - 2023)

Jasper Therapeutics has reported Receivables - Other for 4 years, with the latest figure at $18000.0 in Q3 2023.

• On a quarterly basis, Receivables - Other fell 84.62% year-over-year to $18000.0 in Q3 2023; TTM through Dec 2023 was -$1.3 million, a 290.5% decrease from a year earlier, with the FY2023 full-year figure at -$663000.0, down 200.0% from the prior year.
• Receivables - Other was $18000.0 for Q3 2023 at Jasper Therapeutics, down from $53000.0 in the prior quarter.
• The five-year high for Receivables - Other was $663000.0 in Q4 2022, with the low at -$663000.0 in Q1 2023.
• Average Receivables - Other over 4 years is $39900.0, with a median of $49500.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other jumped 342.0% in 2022, then slumped 4520.0% in 2023.
• Over 4 years, Receivables - Other stood at $600000.0 in 2020, then slumped by 75.0% to $150000.0 in 2021, then surged by 342.0% to $663000.0 in 2022, then slumped by 97.29% to $18000.0 in 2023.
• The last three Receivables - Other figures came in at $18000.0 (Q3 2023), $53000.0 (Q2 2023), and -$663000.0 (Q1 2023), per Business Quant data.